WHO Issues First-Ever List Of Essential Diagnostic Tests 15/05/2018 William New The World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Unitaid Calls For Proposals On TB, Hails New Insecticide 07/05/2018 Damilola Adepeju Unitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Unitaid Calls For Proposals On TB, Hails New Insecticide 07/05/2018 Damilola Adepeju Unitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Unitaid Calls For Proposals On TB, Hails New Insecticide 07/05/2018 Damilola Adepeju Unitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Unitaid Calls For Proposals On TB, Hails New Insecticide 07/05/2018 Damilola Adepeju Unitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Unitaid Calls For Proposals On TB, Hails New Insecticide 07/05/2018 Damilola Adepeju Unitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Unitaid Calls For Proposals On TB, Hails New Insecticide 07/05/2018 Damilola Adepeju Unitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
World Health Assembly 2018 Preview: Guide To Key Issues 03/05/2018 Catherine Saez The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Posts navigation Older postsNewer posts